Liver cancer cases to nearly double worldwide by 2050, says study
New cases of liver cancer -- the sixth most common form of the disease -- will rise to 1.52 million a year from 870,000 if current trends continue, according to data from the Global Cancer Observatory published in the Lancet medical journal.
It is also the third deadliest of all cancers, with the study predicting it would take 1.37 million lives by the middle of the century.
However three out of five cases of liver cancer could be prevented, the international team of experts said.
The risk factors are drinking alcohol, viral hepatitis and a build-up of fat in the liver linked to obesity called MASLD, which was previously known as non-alcoholic fatty liver disease.
The viruses that cause hepatitis B and C are expected to remain the leading causes of liver cancer in 2050, according to the study, published on World Hepatitis Day.
Vaccination at birth is the best way to prevent hepatitis B, but vaccine coverage remains low in poorer countries including in sub-Saharan Africa, the study said.
Unless vaccination rates are increased, hepatitis B is expected to kill 17 million people between 2015 and 2030, it added.
Alcohol consumption is estimated to cause more than 21 percent of all cases of liver cancer by 2050, up more than two percentage points from 2022.
Cancer due to obesity-linked fat in livers will rise to 11 percent, also up more than two percentage points, the researchers calculated.
The large-scale study, which reviewed the available evidence on the subject, underscored "the urgent need for global action" on liver cancer, the authors said.
The experts called for more public awareness about the preventable danger of liver cancer, particularly by warning people with obesity or diabetes about fatty-liver disease in the United States, Europe and Asia.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
France 24
3 days ago
- France 24
France says it cannot save contraceptives US plans to destroy
The contraceptives -- intended for some of the world's poorest countries, particularly in sub-Saharan Africa -- were purchased by the US foreign aid agency USAID under former president Joe Biden. But France's health ministry told AFP Friday there was no legal way for it to intervene. The administration of Biden's successor Donald Trump, which has slashed USAID and pursued anti-abortion policies, confirmed last month it planned to destroy the contraceptives, which have been stored in a warehouse in the Belgian city of Geel. According to several media reports, the unexpired products were to be incinerated in France at the end of July by a company that specialises in destroying medical waste. France's government has come under pressure to save the contraceptives, with women's rights groups calling the US decision "insane". The health ministry told AFP that the government had "examined the courses of action available to us, but unfortunately there is no legal basis for intervention by a European health authority, let alone the French national drug safety authority, to recover these medical products. "Since contraceptives are not drugs of major therapeutic interest, and in this case we are not facing a supply shortage, we have no means to requisition the stocks," it added. The ministry also said it had no information on where the contraceptives would be destroyed. Leaving Belgian warehouse Sarah Durocher, head of the French women's rights group Family Planning, told AFP that some contraceptives had already left the Belgian warehouse. "We were informed 36 hours ago that the removal of these boxes of contraceptives had begun," Durocher said Thursday. "We do not know where these trucks are now -- or whether they have arrived in France," she added. "We call on all incineration companies not to destroy the contraceptives and to oppose this insane decision." French company Veolia confirmed to AFP that it had a contract with the US firm Chemonics, USAID's logistics provider. But Veolia emphasised that the contract concerned "only the management of expired products, which is not the case for the stockpile" in Belgium. The products, mostly long-acting contraceptives such as IUDs and birth control implants, are reportedly up to five years away from expiring. Outrage over decision The US decision has provoked an outcry in France, where rights groups and left-wing politicians have called on their government to stop the plan. "France cannot become the scene of such operations -- a moratorium is essential," an opinion piece in the French daily Le Monde said Friday. Signed by five NGOs, it condemned the "absurdity" of the US decision. Among them was MSI Reproductive Choices, one of several organisations that have offered to purchase and repackage the contraceptives at no cost to the US government. All offers have been rejected. Last week, New Hampshire's Democratic Senator Jeanne Shaheen pointed to the Trump administration's stated goal of reducing government waste, saying the contraceptives plan "is the epitome of waste, fraud and abuse". A US State Department spokesperson told AFP earlier this week that the destruction of the products would cost $167,000 and "no HIV medications or condoms are being destroyed". The spokesperson pointed to a policy that prohibits providing aid to non-governmental organisations that perform or promote abortions. The Mexico City Policy, which critics call the "global gag rule", was first introduced by President Ronald Reagan in 1984. It has been reinstated under every Republican president since.
Euronews
6 days ago
- Euronews
Liver cancer cases could double by 2050, but 60% are preventable
Liver cancer is on the rise, but experts say it doesn't have to be this way. A new analysis published by an expert panel on liver cancer has shown that three out of five liver cancer cases worldwide are linked to preventable risk factors. These include viral hepatitis, alcohol consumption, and an increasingly common but often overlooked threat: obesity-related liver disease. Without urgent intervention, the number of liver cancer cases is expected to nearly double from 870,000 in 2022 to 1.52 million by 2050, with annual deaths rising from 760,000 to 1.37 million. But experts argue that millions of lives can be saved with targeted prevention and policy reforms. Liver cancer "is one of the most challenging cancers to treat, with five-year survival rates ranging from approximately 5 per cent to 30 per cent,' said Jian Zhou, a professor at Fudan University in China and chair of the Lancet commission. 'We risk seeing close to a doubling of cases and deaths from liver cancer over the next quarter of a century without urgent action to reverse this trend,' Zhou said in a statement. A shifting landscape of risk Traditionally associated with hepatitis infections and heavy alcohol use, liver cancer is now being increasingly driven by metabolic dysfunction-associated steatotic liver disease (MASLD), once commonly known as non-alcoholic fatty liver disease. MASLD is one of the most common liver conditions in Europe, affecting up to 25 per cent of the adult population, Beatrice Credi of the European Liver Patients' Association (ELPA) told Euronews Health. 'It is crucial to stress that while these risk factors are prevalent, they are often preventable or manageable with appropriate intervention,' she added, emphasising the importance of education as well as robust public health campaigns. This long-term liver condition is linked to obesity and poor metabolic health. Its more severe form, known as MASH (metabolic dysfunction-associated steatohepatitis), is the fastest-growing cause of liver cancer globally. The Lancet commission projects that liver cancers linked to MASH will increase by 35 per cent, rising from 8 per cent of cases in 2022 to 11 per cent by 2050. Liver cancers related to alcohol are also expected to rise modestly. Meanwhile, cases caused by hepatitis B and C are predicted to decline slightly thanks to vaccination and improved treatment efforts. Numbers are particularly concerning in high-income countries, where obesity rates are soaring. In the United States, MASLD is expected to affect more than half of all adults by 2040, dramatically increasing liver cancer risk. According to Dr Hashem El-Serag, a professor at Baylor College of Medicine, the profile of the disease is evolving. 'Liver cancer was once thought to occur mainly in patients with viral hepatitis or alcohol-related liver disease,' he said. But with obesity on the rise, it is becoming an increasingly prominent risk factor, largely due to growing cases of excess liver fat. The prevention opportunity Despite the grim projections, the Lancet commission offers a glimmer of hope: the potential of prevention. If new liver cancer cases are reduced by 2 per cent to 5 per cent each year, it could prevent up to 17 million new cases and save as many as 15 million lives by 2050. Achieving that would require a multi-pronged global effort, including expanding hepatitis B vaccination and universal adult HBV screening, as well as tackling obesity and alcohol misuse through taxes, warning labels, and better food and beverage policies. The Lancet commission also suggests integrating liver screening into routine care for people with obesity, diabetes, and heart disease and investing in public education and early detection tools. 'As three in five cases of liver cancer are linked to preventable risk factors ... there is a huge opportunity for countries to target these risk factors, prevent cases of liver cancer, and save lives,' said Stephen Chan, lead author of the study and a professor ar the Chinese University of Hong Kong. A global call to action In Europe, recent policy shifts have increasingly emphasised prevention and early detection. The European Union's Beating Cancer Plan aims to achieve 95 per cent coverage for childhood hepatitis B vaccination and screening of pregnant women by 2030. It also encourages healthier lifestyle choices and aims to reduce exposure to known risk factors such as alcohol, tobacco, obesity, and diabetes. A policy recommendation issued by the European Commission in January called for expanded uptake of preventive vaccines (specifically HPV and hepatitis B) and improved monitoring of vaccine coverage rates. But in the fight against liver cancer, the EU must also confront a less visible but equally powerful force: the commercial determinants of health, said ELPA's Beatrice Credi. 'Industries that profit from the sale of alcohol, unhealthy foods, and tobacco play a significant role in driving some of the liver cancer risk factors. Our policymakers must prioritise public health,' she told Euronews Health. She noted, however, that policies aimed at regulating these commercial influences remain weak or inconsistently enforced across the EU, with the only exception of taxes on sugar-sweetened beverages. Prevention alone is not enough. As more people are now living with liver cancer than ever before, the Lancet commission stressed the urgent need for improved care, earlier diagnosis, and better support for patients—especially in regions such as Africa and Asia, where the disease burden is highest and health care resources are limited. But Valérie Paradis, a professor at Beaujon Hospital in France, suggested effective prevention could also help ease that burden. 'Compared with other cancers, liver cancer is very hard to treat but has more distinct risk factors, which help define specific prevention strategies,' Paradis said.
France 24
7 days ago
- France 24
Liver cancer cases to nearly double worldwide by 2050, says study
The number of people with liver cancer will nearly double worldwide by 2050 unless more is done to address preventable causes such as obesity, alcohol consumption and hepatitis, a study warned Tuesday. New cases of liver cancer -- the sixth most common form of the disease -- will rise to 1.52 million a year from 870,000 if current trends continue, according to data from the Global Cancer Observatory published in the Lancet medical journal. It is also the third deadliest of all cancers, with the study predicting it would take 1.37 million lives by the middle of the century. However three out of five cases of liver cancer could be prevented, the international team of experts said. The risk factors are drinking alcohol, viral hepatitis and a build-up of fat in the liver linked to obesity called MASLD, which was previously known as non-alcoholic fatty liver disease. The viruses that cause hepatitis B and C are expected to remain the leading causes of liver cancer in 2050, according to the study, published on World Hepatitis Day. Vaccination at birth is the best way to prevent hepatitis B, but vaccine coverage remains low in poorer countries including in sub-Saharan Africa, the study said. Unless vaccination rates are increased, hepatitis B is expected to kill 17 million people between 2015 and 2030, it added. Alcohol consumption is estimated to cause more than 21 percent of all cases of liver cancer by 2050, up more than two percentage points from 2022. Cancer due to obesity-linked fat in livers will rise to 11 percent, also up more than two percentage points, the researchers calculated. The large-scale study, which reviewed the available evidence on the subject, underscored "the urgent need for global action" on liver cancer, the authors said. The experts called for more public awareness about the preventable danger of liver cancer, particularly by warning people with obesity or diabetes about fatty-liver disease in the United States, Europe and Asia.
